

## Special Issue

# Novel Nanoparticle Formulations for Retinal Drug Delivery

### Message from the Guest Editor

The delivery of drugs intended to reach the retina is very complex. Nanocarriers, such as nanoparticles, can deliver ophthalmic drugs to specific targets and promise to revolutionise the treatment of many eye diseases. To date, the results strongly suggest that ophthalmology stands to benefit enormously from the use of this nanotechnology. In recent decades, nanotechnology appears to be creating new horizons for the treatment of ocular diseases by enabling the controlled release of drugs, ensuring fewer side effects, improving drug bioavailability, and forcing drug uptake into retinal cells. Numerous drug delivery systems have also been investigated regarding their ability to reach the posterior segment of the eye through topical application. The aim of this Special Issue is to provide an update on recent advancements in the synthesis, development and use of nanoparticles for drug delivery and sustained release in the retina, in view of the practical potential of nanoparticles and nanoformulations.

---

### Guest Editor

Dr. José Hurst

University Eye Hospital Tuebingen, Elfriede-Aulhorn - Str. 7, 72076  
Tübingen, Germany

---

### Deadline for manuscript submissions

closed (20 November 2023)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/140827](https://mdpi.com/si/140827)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).